AI acceleration for pharma drug development
AI is transforming drug development from a slow, linear process into a fast, data‑driven engine for discovery. Models that can predict targets, design molecules, and optimize trials are already cutting years off development timelines and reducing risk at every stage. But this acceleration also forces pharma to rethink data quality, regulatory expectations, and how human expertise and AI should work together. In this roundtable, we’ll explore where AI is delivering real impact today and what it will take to scale these breakthroughs across the industry.
Host: Stina Wallmark, Investment Director (Voima Ventures)
About the company:
Voima Ventures is a Nordic & Baltic early‑stage deep tech fund backing science‑driven founders who are solving global problems through breakthrough technologies. While our roots are in deep tech across fields like advanced materials, quantum, and life sciences, we’ve also become a leading early investor in AI‑powered health innovation. Our portfolio includes companies building AI operating systems for oncology professionals, cutting‑edge epigenetic screening and drug‑discovery platforms and next‑generation diagnostics for neurological diseases such as Parkinson’s. As the host of this roundtable, we’re excited to bring together experts who are shaping how AI accelerates drug development and transforms the future of medicine.
Welcome to sign up to participate in the discussion and/or listen in.
INVESTOR TICKET REQUIRED